Dosage guide
Alpha-GPC dosage
Alpha-GPC dosing: typical range, frequency, half-life, onset, routes. Evidence-tiered.
At a glance
- Typical dose
- 600mg
- Half-life
- 4hr
- Frequency
- 1 to 3 times daily
- Routes
- oral
Protocol
- 1
Measure the dose
Typical Alpha-GPC dose is 600 mg (Supplement use 300 to 600 mg/day; European prescription dose 1,200 mg/day for vascular cognitive impairment). Use a weight-based calculator for individual adjustments.
Open tool → - 2
Set the frequency
Administer 1 to 3 times daily. Half-life of 4 hours anchors the dosing interval.
Open tool → - 3
Cycle if needed
No formal cycling required; long-term continuous use documented in European prescription practice
Open tool → - 4
Monitor for side effects
Watch for: mild GI upset; headache; dizziness; occasional insomnia with evening dosing. Stop or reduce dose if tolerability breaks down.
Why this dose
Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS.
The typical dose (600 mg) reflects Supplement use 300 to 600 mg/day; European prescription dose 1,200 mg/day for vascular cognitive impairment. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.
How to administer
Alpha-GPC is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.
Onset of action runs around 1 hour after administration. Peak effect lands near 2 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.
Half-life note: Free choline plasma half-life around 4 hours after oral dosing
Cycling and tolerance
No formal cycling required; long-term continuous use documented in European prescription practice
Effects to expect at typical dose
- Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
- Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
- Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
- ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
- Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
- TMAO production raises a contested cardiovascular concern at chronic high doses
Best-graded outcomes
- B Vascular cognitive impairment cognitive function : Improved MMSE and ADAS-cog over 6 to 24 months (Vascular cognitive impairment, 1,200 mg/day).
- B Adjunct to donepezil in Alzheimer's : Greater cognitive preservation versus donepezil alone (ASCOMALVA combination therapy).
- B TMAO production : Detectable TMAO elevation at chronic high doses (Choline supplementation studies).
Side effects and interactions
Common side effects
- mild GI upset
- headache
- dizziness
- occasional insomnia with evening dosing
Notable interactions
- anticholinergic medications (minor): partial mutual antagonism
- cholinesterase inhibitors (donepezil) (minor): additive cholinergic effect, basis for ASCOMALVA protocol
- scopolamine (minor): partial counteraction of anticholinergic effect
Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Alpha-GPC profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.
Regulatory snapshot
- WADA status
- allowed
- DEA / Rx
- OTC supplement
- Pregnancy
- Insufficient data; choline generally recommended in pregnancy
- Legal status
- Dietary supplement (US); prescription medication in much of Europe
Do not use if
- established cardiovascular disease (TMAO concern)
- concurrent strong anticholinergic therapy
Related calculators
Related research